Zenith开窗与腹主动脉支架的前瞻性 pivotal 试验中肾脏结局比较
两项前瞻性非随机研究倾向性匹配比较了67例开窗腔内修复(FEVAR)与134例腹主动脉腔内修复(EVAR)患者,术前eGFR均>45 mL/min。平均随访30±20个月,两组肾功能恶化速率相似,但FEVAR组肾动脉狭窄/闭塞及肾脏相关再干预更多,进展至透析率低且相同(1.5% vs 1.5%)。
要点
- FEVAR与EVAR术后eGFR下降>25%及进展至CKD IV-V期的比例无显著差异。
- FEVAR组肾动脉狭窄/闭塞(22% vs 2%)及肾脏相关再干预(18% vs 3%)显著更高。
- 两组进展至需透析的肾衰竭率均低且相同(1.5% vs 1.5%)。
核心结论
- 在术前肾功能保留的患者中,FEVAR与EVAR术后肾功能恶化速率相似。
- FEVAR术后肾脏相关再干预率更高,但两组净肾功能变化相似。
研究设计与样本
- 两项前瞻性、非随机研究,评估Zenith开窗与腹主动脉支架。
- 纳入术前eGFR>45 mL/min患者,按年龄、性别、高血压、糖尿病和术前eGFR进行1:2倾向性评分匹配。
- FEVAR组67例,EVAR匹配对照组134例,平均随访30±20个月。
主要发现
- 1个月时eGFR下降>25%:FEVAR 5% vs EVAR 9%(p=.39)。
- 2年eGFR下降>25%:FEVAR 20% vs EVAR 20%(p>.99);5年:FEVAR 27% vs EVAR 50%(p=.50)。
- 进展至CKD IV-V期:2年FEVAR 2% vs EVAR 3%(p>.99);5年FEVAR 7% vs EVAR 8%(p>.99)。
- 随访期间肾动脉狭窄/闭塞:FEVAR 15/67(22%) vs EVAR 3/134(2%)(p<.001)。
- 肾脏相关再干预:FEVAR 12/67(18%) vs EVAR 4/134(3%)(p<.001)。
关键数值与推荐
- AKI定义采用RIFLE标准。
- 肾功能保留定义为术前eGFR>45 mL/min。
- 结局包括sCr、eGFR变化及CKD分期进展至5年。
临床怎么用
- 对于术前肾功能保留的复杂腹主动脉瘤患者,FEVAR与EVAR的肾功能恶化风险相似。
- FEVAR术后需更密切监测肾动脉狭窄/闭塞及肾脏相关再干预。
局限性
- 研究为非随机设计,尽管采用倾向性评分匹配。
- 样本量较小(FEVAR 67例,EVAR 134例)。
- 5年随访数据可能不完整或事件数少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: Fenestrated endovascular repair (FEVAR) has been used to treat complex abdominal aortic aneurysms (AAAs). The risk of renal function deterioration compared with infrarenal endovascular aortic repair (EVAR) has not been determined. METHODS: Patients with preserved renal function (estimated glomerular filtration rate [eGFR] > 45 mL/minute) enrolled in two prospective, non-randomised studies evaluating Zenith fenestrated and AAA stent grafts were matched (1:2) by propensity scores for age, sex, hypertension, diabetes, and pre-operative eGFR. Sixty-seven patients were treated by FEVAR and 134 matched controls treated by EVAR. Mean follow-up was 30 ± 20 months. Outcomes included acute kidney injury (AKI) defined by RIFLE and changes in serum creatinine (sCr), eGFR, and chronic kidney disease (CKD) staging up to 5 years. RESULTS: AKI at 1 month was similar between groups, with > 25% decline in eGFR observed in 5% of FEVAR and 9% of EVAR patients (p = .39). There were no significant differences in > 25% decline in eGFR at 2 years (FEVAR 20% vs. EVAR 20%; p > .99) or 5 years (FEVAR 27% vs. EVAR 50%; p = .50). Progression to stage IV-V CKD was similar at 2 years (FEVAR 2% vs. EVAR 3%; p > .99) and 5 years (FEVAR 7% vs. EVAR 8%; p > .99), with similar sCr and eGFR up to 5 years. During follow-up, there were more renal artery stenosis/occlusions (15/67 [22%] vs. 3/134 [2%]; p < .001) and renal related re-interventions (12/67 [18%] vs. 4/134 [3%]; p < .001) in patients treated by FEVAR. Rate of progression to renal failure requiring dialysis was low and identical in both groups (1.5% vs. 1.5%; p > .99). CONCLUSION: Aortic repair with FEVAR and EVAR was associated with similar rates of renal function deterioration in patients with preserved pre-operative renal function. Renal related re-interventions were higher following FEVAR, although net changes in renal function were similar in both groups.
引用
- de Souza LR, Oderich GS, Farber MA, et al. Editor's Choice - Comparison of Renal Outcomes in Patients Treated by Zenith® Fenestrated and Zenith® Abdominal Aortic Aneurysm Stent grafts in US Prospective Pivotal Trials. Eur J Vasc Endovasc Surg. 2017. PMID: 28285957. doi:10.1016/j.ejvs.2017.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。